name: Level 7 molecular pathology procedure - Full gene sequence analysis of hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase [trifunctional protein] alpha subunit (HADHA) for evaluation of long chain acyl-coenzyme A dehydrogenase deficiency


name: Level 7 molecular pathology procedure - Full gene sequence analysis of hydroxymethylbilane synthase (HMBS) for the evaluation of acute intermittent porphyria


name: Level 7 molecular pathology procedure - Full gene sequence analysis of iduronidase, alpha-L- (IDUA) for evaluation of mucopolysaccharidosis type I


name: Level 7 molecular pathology procedure - Full gene sequence analysis of inverted formin, FH2 and WH2 domain containing (INF2) for evaluation of focal segmental glomerulosclerosis


name: Level 7 molecular pathology procedure - Full gene sequence analysis of isovaleryl-CoA dehydrogenase (IVD) for the evaluation of isovaleric acidemia


name: Level 7 molecular pathology procedure - Full gene sequence analysis of junction plakoglobin (JUP) for evaluation of arrhythmogenic right ventricular dysplasia/cardiomyopathy 11


name: Level 7 molecular pathology procedure - Full gene sequence analysis of lamin A/C (LMNA) for evaluation of Emery-Dreifuss muscular dystrophy (EDMD 1, 2 and 3)


name: Level 7 molecular pathology procedure - Full gene sequence analysis of lamin A/C (LMNA) for evaluation of dilated cardiomyopathy (CMD1A)


name: Level 7 molecular pathology procedure - Full gene sequence analysis of lamin A/C (LMNA) for evaluation of familial partial lipodystrophy (FPLD2)


name: Level 7 molecular pathology procedure - Full gene sequence analysis of lamin A/C (LMNA) for evaluation of limb-girdle muscular dystrophy (LGMD) type 1B


name: Level 7 molecular pathology procedure - Full gene sequence analysis of leptin receptor (LEPR) for the evaluation of obesity with hypogonadism


name: Level 7 molecular pathology procedure - Full gene sequence analysis of low density lipoprotein receptor (LDLR) for evaluation of familial hypercholesterolemia


name: Level 7 molecular pathology procedure - Full gene sequence analysis of low density lipoprotein receptor-related protein 5 (LRP5) for evaluation of osteopetrosis


name: Level 7 molecular pathology procedure - Full gene sequence analysis of luteinizing hormone/choriogonadotropin receptor (LHCGR) for evaluation of precocious male puberty


name: Level 7 molecular pathology procedure - Full gene sequence analysis of methylcrotonoyl-CoA carboxylase 1 [alpha] (MCCC1) for evaluation of 3-methylcrotonyl-CoA carboxylase deficiency


name: Level 7 molecular pathology procedure - Full gene sequence analysis of methylcrotonoyl-CoA carboxylase 2 [beta] (MCCC2) for evaluation of 3-methylcrotonyl carboxylase deficiency


name: Level 7 molecular pathology procedure - Full gene sequence analysis of methylmalonyl CoA mutase (MUT) for evaluation of methylmalonic acidemia


name: Level 7 molecular pathology procedure - Full gene sequence analysis of microtubule-associated protein tau (MAPT) for evaluation of frontotemporal dementia


name: Level 7 molecular pathology procedure - Full gene sequence analysis of mitogen-activated protein kinase 1 (MAP2K1) for the evaluation of cardiofaciocutaneous syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of mitogen-activated protein kinase 2 (MAP2K2) for evaluation of cardiofaciocutaneous syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of myotubularin 1 (MTM1) for evaluation of X-linked centronuclear myopathy


name: Level 7 molecular pathology procedure - Full gene sequence analysis of nephronophthisis 1 [juvenile] (NPHP1) for evaluation of Joubert syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of neurofibromin 2 [merlin](NF2) for evaluation of neurofibromatosis, type 2


name: Level 7 molecular pathology procedure - Full gene sequence analysis of nuclear receptor binding SET domain protein 1 (NSD1) for evaluation of Sotos syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of optineurin (OPTN) for evaluation of amyotrophic lateral sclerosis


name: Level 7 molecular pathology procedure - Full gene sequence analysis of paired box 2 (PAX2) for evaluation of renal coloboma syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of paroxysmal nonkinesigenic dyskinesia (PNKD) for the evaluation of paroxysmal nonkinesigenic dyskinesia


name: Level 7 molecular pathology procedure - Full gene sequence analysis of phenylalanine hydroxylase (PAH) for evaluation of phenylketonuria


name: Level 7 molecular pathology procedure - Full gene sequence analysis of phosphate-regulating endopeptidase homolog, X-linked (PHEX) for evaluation of hypophosphatemic rickets


name: Level 7 molecular pathology procedure - Full gene sequence analysis of plakophilin 2 (PKP2) for evaluation of arrhythmogenic right ventricular dysplasia/cardiomyopathy 9


name: Level 7 molecular pathology procedure - Full gene sequence analysis of platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 [45kDa] (PAFAH1B1) for evaluation of Miller-Dieker syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 [45kDa] (PAFAH1B1) for evaluation of lissencephaly


name: Level 7 molecular pathology procedure - Full gene sequence analysis of polycystic kidney disease 2 [autosomal dominant] (PKD2) polycystic kidney disease


name: Level 7 molecular pathology procedure - Full gene sequence analysis of polymerase [DNA directed], gamma (POLG) for evaluation of Alpers-Huttenlocher syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of polymerase [DNA directed], gamma (POLG) for evaluation of autosomal dominant progressive external ophthalmoplegia


name: Level 7 molecular pathology procedure - Full gene sequence analysis of potassium voltage-gated channel, KQT-like subfamily, member 1 (KCNQ1) for evaluation of long QT syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of potassium voltage-gated channel, KQT-like subfamily, member 1 (KCNQ1) for evaluation of short QT syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of potassium voltage-gated channel, KQT-like subfamily, member 2 (KCNQ2) for evaluation of epileptic encephalopathy


name: Level 7 molecular pathology procedure - Full gene sequence analysis of potassium voltage-gated channel, subfamily H [eag-related], member 2 (KCNH2) for evaluation of long QT syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of potassium voltage-gated channel, subfamily H [eag-related], member 2 (KCNH2) for evaluation of short QT syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of presenilin 2 [Alzheimer disease 4] (PSEN2) for evaluation of Alzheimer disease


name: Level 7 molecular pathology procedure - Full gene sequence analysis of propionyl CoA carboxylase, alpha polypeptide (PCCA) for evaluation of propionic acidemia, type 1


name: Level 7 molecular pathology procedure - Full gene sequence analysis of propionyl CoA carboxylase, beta polypeptide (PCCB) for evaluation of propionic acidemia


name: Level 7 molecular pathology procedure - Full gene sequence analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) for evaluation of familial hypercholesterolemia


name: Level 7 molecular pathology procedure - Full gene sequence analysis of protein O-linked mannose beta1,2-N acetylglucosaminyltransferase (POMGNT1) for evaluation of Walker-Warburg syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of protein O-linked mannose beta1,2-N acetylglucosaminyltransferase (POMGNT1) for evaluation of muscle-eye-brain disease


name: Level 7 molecular pathology procedure - Full gene sequence analysis of protein kinase C, gamma (PRKCG) for evaluation of spinocerebellar ataxia


name: Level 7 molecular pathology procedure - Full gene sequence analysis of protein kinase, AMP-activated, gamma 2 noncatalytic subunit (PRKAG2) for evaluation of familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of protein kinase, AMP-activated, gamma 2 noncatalytic subunit (PRKAG2) for evaluation of lethal congenital glycogen storage disease of heart


name: Level 7 molecular pathology procedure - Full gene sequence analysis of protein tyrosine phosphatase, non-receptor type 11 (PTPN11) for evaluation of LEOPARD syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of protein tyrosine phosphatase, non-receptor type 11 (PTPN11) for evaluation of Noonan syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of protein-O-mannosyltransferase 1 (POMT1) for evaluation of Walker-Warburg syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of protein-O-mannosyltransferase 1 (POMT1) for evaluation of limb-girdle muscular dystrophy (LGMD) type 2K


name: Level 7 molecular pathology procedure - Full gene sequence analysis of protein-O-mannosyltransferase 2 (POMT2) for evaluation of Walker-Warburg syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of protein-O-mannosyltransferase 2 (POMT2) for evaluation of limb-girdle muscular dystrophy (LGMD) type 2N


name: Level 7 molecular pathology procedure - Full gene sequence analysis of protoporphyrinogen oxidase (PPOX) for evaluation of variegate porphyria


name: Level 7 molecular pathology procedure - Full gene sequence analysis of pyruvate carboxylase (PC) for evaluation of pyruvate carboxylase deficiency


name: Level 7 molecular pathology procedure - Full gene sequence analysis of pyruvate dehydrogenase [lipoamide] alpha 1 (PDHA1) for evaluation of lactic acidosis


name: Level 7 molecular pathology procedure - Full gene sequence analysis of pyruvate dehydrogenase complex, component X (PDHX) lactic acidosis


name: Level 7 molecular pathology procedure - Full gene sequence analysis of ret proto-oncogene (RET) for evaluation of Hirschsprung disease


name: Level 7 molecular pathology procedure - Full gene sequence analysis of retinal pigment epithelium-specific protein 65kDa (RPE65) for evaluation of Leber congenital amaurosis


name: Level 7 molecular pathology procedure - Full gene sequence analysis of retinal pigment epithelium-specific protein 65kDa (RPE65) for evaluation of retinitis pigmentosa


name: Level 7 molecular pathology procedure - Full gene sequence analysis of sarcoglycan, epsilon (SGCE) for evaluation of myoclonic dystonia


name: Level 7 molecular pathology procedure - Full gene sequence analysis of senataxin (SETX) for the evaluation of ataxia


name: Level 7 molecular pathology procedure - Full gene sequence analysis of sodium channel, nonvoltage-gated 1 alpha (SCNN1A) for evaluation of pseudohypoaldosteronism


name: Level 7 molecular pathology procedure - Full gene sequence analysis of sodium channel, nonvoltage-gated 1, beta (SCNN1B) for evaluation of Liddle syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of sodium channel, nonvoltage-gated 1, beta (SCNN1B) for evaluation of pseudohypoaldosteronism


name: Level 7 molecular pathology procedure - Full gene sequence analysis of sodium channel, nonvoltage-gated 1, gamma (SCNN1G) for evaluation of Liddle syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of sodium channel, nonvoltage-gated 1, gamma (SCNN1G) for evaluation of pseudohypoaldosteronism


name: Level 7 molecular pathology procedure - Full gene sequence analysis of sodium channel, voltage-gated, type IV, alpha subunit (SCN4A) for evaluation of hyperkalemic periodic paralysis


name: Level 7 molecular pathology procedure - Full gene sequence analysis of solute carrier family 26, member 4 (SLC26A4) for evaluation of Pendred syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of solute carrier family 37 (glucose-6-phosphate transporter) member 4 (SLC37A4) for the evaluation of glycogen storage disease type Ib


name: Level 7 molecular pathology procedure - Full gene sequence analysis of solute carrier family 9 [sodium/hydrogen exchanger], member 6 (SLC9A6) for evaluation of Christianson syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of son of sevenless homolog 1 (SOS1) for evaluation of Noonan syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of son of sevenless homolog 1 (SOS1) for evaluation of gingival fibromatosis


name: Level 7 molecular pathology procedure - Full gene sequence analysis of spastic paraplegia 7 [pure and complicated autosomal recessive] (SPG7) for evaluation of spastic paraplegia


name: Level 7 molecular pathology procedure - Full gene sequence analysis of spastin (SPAST) for evaluation of spastic paraplegia


name: Level 7 molecular pathology procedure - Full gene sequence analysis of succinate dehydrogenase complex, subunit A, flavoprotein [Fp] (SDHA) for evaluation of Leigh syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of succinate dehydrogenase complex, subunit A, flavoprotein [Fp] (SDHA) for evaluation of mitochondrial complex II deficiency


name: Level 7 molecular pathology procedure - Full gene sequence analysis of syntaxin-binding protein 1 (STXBP1) for evaluation of epileptic encephalopathy


name: Level 7 molecular pathology procedure - Full gene sequence analysis of tafazzin (TAZ) for evaluation of Barth syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of tafazzin (TAZ) for evaluation of methylglutaconic aciduria type 2


name: Level 7 molecular pathology procedure - Full gene sequence analysis of transcription factor 4 (TCF4) for evaluation of Pitt-Hopkins syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of transient receptor potential cation channel, subfamily C, member 6 (TRPC6) for evaluation of focal segmental glomerulosclerosis


name: Level 7 molecular pathology procedure - Full gene sequence analysis of transmembrane protein 43 (TMEM43) for evaluation of arrhythmogenic right ventricular cardiomyopathy


name: Level 7 molecular pathology procedure - Full gene sequence analysis of troponin T, type 2 [cardiac] (TNNT2) for evaluation of familial hypertrophic cardiomyopathy


name: Level 7 molecular pathology procedure - Full gene sequence analysis of tuberous sclerosis 1 (TSC1) for evaluation of tuberous sclerosis


name: Level 7 molecular pathology procedure - Full gene sequence analysis of tyrosine hydroxylase (TH) for evaluation of Segawa syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of ubiquitin protein ligase E3A (UBE3A) for evaluation of Angelman syndrome


name: Level 7 molecular pathology procedure - Full gene sequence analysis of uromodulin (UMOD) for evaluation of glomerulocystic kidney disease with hyperuricemia and isosthenuria


name: Level 7 molecular pathology procedure - Full gene sequence analysis of v-raf-1 murine leukemia viral oncogene homolog 1 (RAF1) for evaluation of LEOPARD syndrome


name: Level 7 molecular pathology procedure - Full gene sequence of ATPase, Na+/K+ transporting, alpha 2 polypeptide (ATP1A2) for evaluation of familial hemiplegic migraine


name: Level 7 molecular pathology procedure - Full sequence analysis of hepatocyte nuclear factor 4, alpha (HNF4A) for the evaluation of maturity-onset diabetes of the young (MODY)


name: Level 7 molecular pathology procedure - Fumarylacetoacetate hydrolase [fumarylacetoacetase] (FAH) full gene sequence analysis


name: Level 7 molecular pathology procedure - Fused in sarcoma (FUS) full gene sequence analysis


name: Level 7 molecular pathology procedure - Galactosylceramidase (GALC) full gene sequence analysis


name: Level 7 molecular pathology procedure - Glucosamine [UDP-N-acetyl]-2-epimerase/N-acetylmannosamine kinase (GNE) full gene sequence analysis


name: Level 7 molecular pathology procedure - Glutamate dehydrogenase 1 (GLUD1) full gene sequence analysis


name: Level 7 molecular pathology procedure - Glycyl-tRNA synthetase (GARS) full gene sequence analysis


name: Level 7 molecular pathology procedure - Granulin (GRN) full gene sequence analysis


name: Level 7 molecular pathology procedure - HLCS holocarboxylase synthetase (HLC) full gene sequence analysis


name: Level 7 molecular pathology procedure - Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase [trifunctional protein] beta subunit (HADHB) full gene sequence analysis


name: Level 7 molecular pathology procedure - Hydroxymethylbilane synthase (HMBS) full gene sequence analysis


name: Level 7 molecular pathology procedure - Iduronidase, alpha-L- (IDUA) full gene sequence analysis


name: Level 7 molecular pathology procedure - Inverted formin, FH2 and WH2 domain containing (INF2) full gene sequence analysis


name: Level 7 molecular pathology procedure - Jagged 1 (JAG1) deletion analysis


name: Level 7 molecular pathology procedure - Jagged 1 (JAG1) deletion and duplication analysis


name: Level 7 molecular pathology procedure - Jagged 1 (JAG1) duplication analysis


name: Level 7 molecular pathology procedure - Junction plakoglobin (JUP) full gene sequence analysis


name: Level 7 molecular pathology procedure - Leptin receptor (LEPR) full gene sequence analysis


name: Level 7 molecular pathology procedure - Low density lipoprotein receptor (LDLR) full gene sequence analysis


name: Level 7 molecular pathology procedure - Low density lipoprotein receptor-related protein 5 (LRP5) full gene sequence analysis


name: Level 7 molecular pathology procedure - Luteinizing hormone/choriogonadotropin receptor (LHCGR) full gene sequence analysis


name: Level 7 molecular pathology procedure - Methylcrotonoyl-CoA carboxylase 1 [alpha] (MCCC1) full gene sequence analysis


name: Level 7 molecular pathology procedure - Methylmalonyl CoA mutase (MUT) full gene sequence analysis


name: Level 7 molecular pathology procedure - Microtubule-associated protein tau (MAPT) full gene sequence analysis


name: Level 7 molecular pathology procedure - Mitofusin 2 (MFN2) full gene sequence analysis


name: Level 7 molecular pathology procedure - Mitogen-activated protein kinase 2 (MAP2K2) full gene sequence analysis


name: Level 7 molecular pathology procedure - Mutation scanning of variants of 26-50 exons


name: Level 7 molecular pathology procedure - Myotubularin 1 (MTM1) full gene sequence analysis


name: Level 7 molecular pathology procedure - NADH dehydrogenase [ubiquinone] Fe-S protein 1, 75kDa [NADH-coenzyme Q reductase] (NDUFS1) full gene sequence analysis


name: Level 7 molecular pathology procedure - Nephronophthisis 1 [juvenile] (NPHP1) full gene sequence analysis


name: Level 7 molecular pathology procedure - Niemann-Pick disease, type C1 (NPC1) full gene sequence analysis


name: Level 7 molecular pathology procedure - Optic atrophy 1 (OPA1) deletion analysis


name: Level 7 molecular pathology procedure - Optic atrophy 1 (OPA1) deletion and duplication analysis


name: Level 7 molecular pathology procedure - Optic atrophy 1 (OPA1) duplication analysis


name: Level 7 molecular pathology procedure - Optineurin (OPTN) full gene sequence analysis


name: Level 7 molecular pathology procedure - Parkinson protein 3, E3 ubiquitin protein ligase (parkin) (PARK2) full gene sequence analysis


name: Level 7 molecular pathology procedure - Paroxysmal nonkinesigenic dyskinesia (PNKD) full gene sequence analysis


name: Level 7 molecular pathology procedure - Phosphate-regulating endopeptidase homolog, X-linked (PHEX) full gene sequence analysis


name: Level 7 molecular pathology procedure - Plakophilin 2 (PKP2) full gene sequence analysis


name: Level 7 molecular pathology procedure - Platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 [45kDa] (PAFAH1B1) full gene sequence analysis


name: Level 7 molecular pathology procedure - Polycystic kidney disease 2 [autosomal dominant] (PKD2) full gene sequence analysis


name: Level 7 molecular pathology procedure - Potassium voltage-gated channel, KQT-like subfamily, member 1 (KCNQ1) full gene sequence analysis


name: Level 7 molecular pathology procedure - Potassium voltage-gated channel, KQT-like subfamily, member 2 (KCNQ2) full gene sequence analysis


name: Level 7 molecular pathology procedure - Potassium voltage-gated channel, subfamily H [eag-related], member 2 (KCNH2) full gene sequence analysis


name: Level 7 molecular pathology procedure - Propionyl CoA carboxylase, alpha polypeptide (PCCA) full gene sequence analysis


name: Level 7 molecular pathology procedure - Proprotein convertase subtilisin/kexin type 9 (PCSK9) full gene sequence analysis


name: Level 7 molecular pathology procedure - Protein kinase C, gamma (PRKCG) full gene sequence analysis


name: Level 7 molecular pathology procedure - Protocadherin-related 15 (PCDH15) deletion analysis


name: Level 7 molecular pathology procedure - Protocadherin-related 15 (PCDH15) deletion and duplication analysis


name: Level 7 molecular pathology procedure - Protocadherin-related 15 (PCDH15) duplication analysis


name: Level 7 molecular pathology procedure - Retinal pigment epithelium-specific protein 65kDa (RPE65) full gene sequence analysis


name: Level 7 molecular pathology procedure - SH3 domain and tetratricopeptide repeats 2 (SH3TC2) full gene sequence analysis


name: Level 7 molecular pathology procedure - SMAD family member 4 (SMAD4) full gene sequence analysis


name: Level 7 molecular pathology procedure - Sarcoglycan, epsilon (SGCE) full gene sequence analysis


name: Level 7 molecular pathology procedure - Senataxin (SETX) full gene sequence analysis


name: Level 7 molecular pathology procedure - Sodium channel, nonvoltage-gated 1 alpha (SCNN1A) full gene sequence analysis


name: Level 7 molecular pathology procedure - Sodium channel, nonvoltage-gated 1, beta (SCNN1B) full gene sequence analysis


name: Level 7 molecular pathology procedure - Sodium channel, nonvoltage-gated 1, gamma (SCNN1G) full gene sequence analysis


name: Level 7 molecular pathology procedure - Sodium channel, voltage-gated, type IV, alpha subunit (SCN4A) full gene sequence analysis


name: Level 7 molecular pathology procedure - Solute carrier family 37 (glucose-6-phosphate transporter) member 4 (SLC37A4) full gene sequence analysis


name: Level 7 molecular pathology procedure - Spastic paraplegia 7 [pure and complicated autosomal recessive] (SPG7) full gene sequence analysis


name: Level 7 molecular pathology procedure - Spastin (SPAST) full gene sequence analysis


name: Level 7 molecular pathology procedure - Succinate dehydrogenase complex, subunit A, flavoprotein [Fp] (SDHA) full gene sequence analysis


name: Level 7 molecular pathology procedure - Syntaxin-binding protein 1 (STXBP1) full gene sequence analysis


name: Level 7 molecular pathology procedure - Targeted sequence analysis of exon 11-16 of von Willebrand factor (VWF) for the evaluation of von Willebrand disease type 2A


name: Level 7 molecular pathology procedure - Targeted sequence analysis of exon 24-26 of von Willebrand factor (VWF) for the evaluation of von Willebrand disease type 2A


name: Level 7 molecular pathology procedure - Targeted sequence analysis of exon 51 of von Willebrand factor (VWF) for the evaluation of von Willebrand disease type 2A


name: Level 7 molecular pathology procedure - Targeted sequence analysis of exon 52 of von Willebrand factor (VWF) for the evaluation of von Willebrand disease type 2A


name: Level 7 molecular pathology procedure - Targeted sequence analysis of exons 1-23 of notch 3 (NOTCH3) for evaluation of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)


name: Level 7 molecular pathology procedure - Targeted sequence analysis of notch 3 (NOTCH3) for evaluation of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)


name: Level 7 molecular pathology procedure - Targeted sequence analysis of ryanodine receptor 1, skeletal (RYR1) of exons with functionally-confirmed mutations for evaluation of malignant hyperthermia


name: Level 7 molecular pathology procedure - Transcription factor 4 (TCF4) full gene sequence analysis


name: Level 7 molecular pathology procedure - Transient receptor potential cation channel, subfamily C, member 6 (TRPC6) full gene sequence analysis


name: Level 7 molecular pathology procedure - Transmembrane protein 43 (TMEM43) full gene sequence analysis


name: Level 7 molecular pathology procedure - Tuberous sclerosis 2 (TSC2) deletion analysis


name: Level 7 molecular pathology procedure - Tuberous sclerosis 2 (TSC2) deletion and detection analysis


name: Level 7 molecular pathology procedure - Tuberous sclerosis 2 (TSC2) detection analysis


name: Level 7 molecular pathology procedure - Tyrosine hydroxylase (TH) full gene sequence analysis


name: Level 7 molecular pathology procedure - Uromodulin (UMOD) full gene sequence analysis


name: Level 7 molecular pathology procedure - Wiskott-Aldrich syndrome [eczema-thrombocytopenia] (WAS) full gene sequence analysis


name: Level 7 molecular pathology procedure -Detection analysis of tuberous sclerosis 2 (TSC2) for evaluation of tuberous sclerosis


name: Level 7 molecular pathology procedure -Duplication analysis of coagulation factor VIII (F8) for evaluation of hemophilia A


name: Level 7 molecular pathology procedure Full gene sequence analysis of mitofusin 2 (MFN2) for evaluation of Charcot-Marie-Tooth disease


name: Level 7 molecular pathology procedure- Protoporphyrinogen oxidase (PPOX) full gene sequence analysis


name: Molecular pathology procedure level 8 genetic analysis


name: Level 8 molecular pathology procedure - Abelson helper integration site 1 (AHI1) full gene sequence analysis


name: Level 8 molecular pathology procedure - Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase (AGL) full gene sequence analysis


name: Level 8 molecular pathology procedure - Analysis of 26-50 exons by DNA sequence analysis


name: Level 8 molecular pathology procedure - Asp (abnormal spindle homolog) microcephaly associated (Drosophilia) (ASPM) full gene sequence analysis


name: Level 8 molecular pathology procedure - CREB binding protein (CREBBP) full gene sequence analysis


name: Level 8 molecular pathology procedure - Collagen, type IV, alpha 4 (COL4A4) full gene sequence analysis


name: Level 8 molecular pathology procedure - Collagen, type IV, alpha 5 (COL4A5) deletion analysis


name: Level 8 molecular pathology procedure - Collagen, type IV, alpha 5 (COL4A5) deletion and duplication analysis


name: Level 8 molecular pathology procedure - Collagen, type IV, alpha 5 (COL4A5) duplication analysis


name: Level 8 molecular pathology procedure - Collagen, type VI, alpha 1 (COL6A1) full gene sequence analysis


name: Level 8 molecular pathology procedure - Collagen, type VI, alpha 2 (COL6A2) full gene sequence analysis


name: Level 8 molecular pathology procedure - Collagen, type VI, alpha 3 (COL6A3) full gene sequence analysis


name: Level 8 molecular pathology procedure - Deletion analysis of collagen, type IV, alpha 5 (COL4A5) for evaluation of Alport syndrome


name: Level 8 molecular pathology procedure - Deletion analysis of vacuolar protein sorting 13 homolog B (yeast) (VPS13B) for evaluation of Cohen syndrome


name: Level 8 molecular pathology procedure - Deletion and duplication analysis of collagen, type IV, alpha 5 (COL4A5) for evaluation of Alport syndrome


name: Level 8 molecular pathology procedure - Deletion and duplication analysis of vacuolar protein sorting 13 homolog B (yeast) (VPS13B) for evaluation of Cohen syndrome


name: Level 8 molecular pathology procedure - Duplication analysis of collagen, type IV, alpha 5 (COL4A5) for evaluation of Alport syndrome


name: Level 8 molecular pathology procedure - Duplication analysis of vacuolar protein sorting 13 homolog B (yeast) (VPS13B) for evaluation of Cohen syndrome


name: Level 8 molecular pathology procedure - Duplication and deletion analysis of variants of more than 50 exons


name: Level 8 molecular pathology procedure - Full gene sequence analysis of ATP-binding cassette, sub-family C (CFTR/MRP), member 8 (ABCC8) for evaluation of familial hyperinsulinism


name: Level 8 molecular pathology procedure - Full gene sequence analysis of CREB binding protein (CREBBP) for evaluation of Rubinstein-Taybi syndrome


name: Level 8 molecular pathology procedure - Full gene sequence analysis of KIAA0196 (KIAA0196) for evaluation of spastic paraplegia


name: Level 8 molecular pathology procedure - Full gene sequence analysis of L1 cell adhesion molecule (L1CAM) for evaluation of MASA syndrome


name: Level 8 molecular pathology procedure - Full gene sequence analysis of L1 cell adhesion molecule (L1CAM) for evaluation of X-linked hydrocephaly


name: Level 8 molecular pathology procedure - Full gene sequence analysis of Usher syndrome 1C (autosomal recessive, severe) (USH1C) for evaluation of Usher syndrome, type 1


name: Level 8 molecular pathology procedure - Full gene sequence analysis of WD repeat domain 62 (WDR62) for evaluation of primary autosomal recessive microcephaly


name: Level 8 molecular pathology procedure - Full gene sequence analysis of abelson helper integration site 1 (AHI1) for evaluation of Joubert syndrome


name: Level 8 molecular pathology procedure - Full gene sequence analysis of amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase (AGL) for evaluation of glycogen storage disease type III


name: Level 8 molecular pathology procedure - Full gene sequence analysis of apolipoprotein B (APOB) for evaluation of familial hypercholesterolemia type B


name: Level 8 molecular pathology procedure - Full gene sequence analysis of asp (abnormal spindle homolog) microcephaly associated (Drosophilia) (ASPM) for evaluation of primary microcephaly


name: Level 8 molecular pathology procedure - Full gene sequence analysis of chromodomain helicase DNA binding protein 7 (CHD7) for evaluation of CHARGE syndrome


name: Level 8 molecular pathology procedure - Full gene sequence analysis of coagulation factor VIII (F8) for evaluation of hemophilia A


name: Level 8 molecular pathology procedure - Full gene sequence analysis of collagen, type IV, alpha 4 (COL4A4) for evaluation of Alport syndrome


name: Level 8 molecular pathology procedure - Full gene sequence analysis of collagen, type VI alpha 1, (COL6A1) for evaluation of collagen type VI-related disorders


name: Level 8 molecular pathology procedure - Full gene sequence analysis of collagen, type VI, alpha 2 (COL6A2) for evaluation of collagen type VI-related disorders


name: Level 8 molecular pathology procedure - Full gene sequence analysis of jagged 1 (JAG1) for evaluation of Alagille syndrome


name: Level 8 molecular pathology procedure - Full gene sequence analysis of laminin, beta 2 (laminin S) (LAMB2) for evaluation of Pierson syndrome


name: Level 8 molecular pathology procedure - Full gene sequence analysis of lysine (K) specific demethylase 5C (KDM5C) for evaluation of X-linked intellectual disability


name: Level 8 molecular pathology procedure - Full gene sequence analysis of myosin VIIA (MYO7A) for evaluation of Usher syndrome, type 1


name: Level 8 molecular pathology procedure - Full gene sequence analysis of myosin binding protein C, cardiac (MYBPC3) for evaluation of familial hypertrophic cardiomyopathy


name: Level 8 molecular pathology procedure - Full gene sequence analysis of myosin, heavy chain 6, cardiac muscle, alpha (MYH6) for evaluation of familial dilated cardiomyopathy


name: Level 8 molecular pathology procedure - Full gene sequence analysis of myosin, heavy chain 7, cardiac muscle, beta (MYH7) for the evaluation of Liang distal myopathy


name: Level 8 molecular pathology procedure - Full gene sequence analysis of myosin, heavy chain 7, cardiac muscle, beta (MYH7) for the evaluation of familial hypertrophic cardiomyopathy


name: Level 8 molecular pathology procedure - Full gene sequence analysis of nephrosis 1, congenital, Finnish type (nephrin) (NPHS1) for evaluation of congenital Finnish nephrosis


name: Level 8 molecular pathology procedure - Full gene sequence analysis of notch 1 (NOTCH1) for analysis of aortic valve disease


name: Level 8 molecular pathology procedure - Full gene sequence analysis of optic atrophy 1 (OPA1) for evaluation of optic atrophy


name: Level 8 molecular pathology procedure - Full gene sequence analysis of phospholipase C, epsilon 1 (PLCE1) for evaluation of nephrotic syndrome type 3


name: Level 8 molecular pathology procedure - Full gene sequence analysis of polycystic kidney disease 1 (autosomal dominant) (PKD1) for evaluation of polycystic kidney disease


name: Level 8 molecular pathology procedure - Full gene sequence analysis of protocadherin-related 15 (PCDH15) for evaluation of Usher syndrome, type 1


name: Level 8 molecular pathology procedure - Full gene sequence analysis of sodium channel, voltage-gated, type 1, alpha subunit (SCN1A) for evaluation of generalized epilepsy with febrile seizures


name: Level 8 molecular pathology procedure - Full gene sequence analysis of sodium channel, voltage-gated, type V, alpha subunit (SCN5A) for evaluation of familial dilated cardiomyopathy


name: Level 8 molecular pathology procedure - Full gene sequence analysis of solute carrier family 12 (sodium/chloride transporters), member 3 (SLC12A3) for evaluation of Gitelman syndrome


name: Level 8 molecular pathology procedure - Full gene sequence analysis of solute carrier family 12 (sodium/potassium/chloride transporters), member 1 (SLC12A1) for evaluation of Bartter syndrome


name: Level 8 molecular pathology procedure - Full gene sequence analysis of spastic paraplegia 11 (autosomal recessive) (SPG11) for evaluation of spastic paraplegia


name: Level 8 molecular pathology procedure - Full gene sequence analysis of spectrin, beta, non-erythrocytic 2 (SPTBN2) for evaluation of spinocerebellar ataxia


name: Level 8 molecular pathology procedure - Full gene sequence analysis of transmembrane protein 67 (TMEM67) for evaluation of Joubert syndrome)


name: Level 8 molecular pathology procedure - Full gene sequence analysis of tuberous sclerosis 2 (TSC2) for evaluation of tuberous sclerosis


name: Level 8 molecular pathology procedure - KIAA0196 (KIAA0196) full gene sequence analysis


name: Level 8 molecular pathology procedure - L1 cell adhesion molecule (L1CAM) full gene sequence analysis


name: Level 8 molecular pathology procedure - Laminin, beta 2 (laminin S) (LAMB2) full gene sequence analysis


name: Level 8 molecular pathology procedure - Lysine (K) specific demethylase 5C (KDM5C) full gene sequence analysis


name: Level 8 molecular pathology procedure - Mutation scanning analysis of variants of more than 50 exons


name: Level 8 molecular pathology procedure - Nephrosis 1, congenital, Finnish type (nephrin) (NPHS1) full gene sequence analysis


name: Level 8 molecular pathology procedure - Phospholipase C, epsilon 1 (PLCE1) full gene sequence analysis


name: Level 8 molecular pathology procedure - Polycystic kidney disease 1 (autosomal dominant) (PKD1) full gene sequence analysis


name: Level 8 molecular pathology procedure - Sequence analysis of multiple genes on one platform


name: Level 8 molecular pathology procedure - Solute carrier family 12 (sodium/chloride transporters), member 3 (SLC12A3) full gene sequence analysis


name: Level 8 molecular pathology procedure - Solute carrier family 12 (sodium/potassium/chloride transporters), member 1 (SLC12A1) full gene sequence analysis


name: Level 8 molecular pathology procedure - Spastic paraplegia 11 (autosomal recessive) (SPG11) full gene sequence analysis


name: Level 8 molecular pathology procedure - Spectrin, beta, non-erythrocytic 2 (SPTBN2) full gene sequence analysis


name: Level 8 molecular pathology procedure - Transmembrane protein 67 (TMEM67) full gene sequence analysis


name: Level 8 molecular pathology procedure - Vacuolar protein sorting 13 homolog B (yeast) (VPS13B) deletion analysis


name: Level 8 molecular pathology procedure - Vacuolar protein sorting 13 homolog B (yeast) (VPS13B) deletion and duplication analysis


name: Level 8 molecular pathology procedure - Vacuolar protein sorting 13 homolog B (yeast) (VPS13B) duplication analysis


name: Level 8 molecular pathology procedure - WD repeat domain 62 (WDR62) full gene sequence analysis


name: Level 8 molecular pathology procedure e- Full gene sequence analysis of collagen, type VI, alpha 3 (COL6A3) for evaluation of collagen type VI-related disorders


name: Molecular pathology procedure level 9 genetic analysis


name: Level 9 molecular pathology procedure - ATP-binding cassette, sub-family A [ABC1], member 4 (ABCA4) full gene sequence analysis


name: Level 9 molecular pathology procedure - Analysis of more than 50 exons in a single gene by DNA sequence analysis


name: Level 9 molecular pathology procedure - Collagen, type IV, alpha 1 (COL4A1) full gene sequence analysis


name: Level 9 molecular pathology procedure - Collagen, type IV, alpha 3 [Goodpasture antigen] (COL4A3) full gene sequence analysis


name: Level 9 molecular pathology procedure - Collagen, type IV, alpha 5 (COL4A5) full gene sequence analysis


name: Level 9 molecular pathology procedure - Dystrophin (DMD) full gene sequence analysis


name: Level 9 molecular pathology procedure - Full gene sequence analysis of Collagen, type IV, alpha 3 [Goodpasture antigen] (COL4A3) for evaluation of Alport syndrome


name: Level 9 molecular pathology procedure - Full gene sequence analysis of TP-binding cassette, sub-family A [ABC1], member 4 (ABCA4) for evaluation of Stargardt disease


name: Level 9 molecular pathology procedure - Full gene sequence analysis of TP-binding cassette, sub-family A [ABC1], member 4 (ABCA4) for evaluation of age-related macular degeneration


name: Level 9 molecular pathology procedure - Full gene sequence analysis of Usher syndrome 2A [autosomal recessive, mild] (USH2A) for evaluation of Usher syndrome, type 2


name: Level 9 molecular pathology procedure - Full gene sequence analysis of ataxia telangiectasia mutated (ATM) for the evaluation of ataxia telangiectasia


name: Level 9 molecular pathology procedure - Full gene sequence analysis of cadherin-related 23 (CDH23) full gene sequence analysis for evaluation of Usher syndrome, type 1


name: Level 9 molecular pathology procedure - Full gene sequence analysis of centrosomal protein 290kDa (CEP290) for evaluation of Joubert syndrome


name: Level 9 molecular pathology procedure - Full gene sequence analysis of collagen, type I, alpha 1 (COL1A1) for evaluation of osteogenesis imperfecta, type I


name: Level 9 molecular pathology procedure - Full gene sequence analysis of collagen, type I, alpha 2 (COL1A2) for evaluation of osteogenesis imperfecta, type I


name: Level 9 molecular pathology procedure - Full gene sequence analysis of collagen, type IV, alpha 1 (COL4A1) for evaluation of brain small-vessel disease with hemorrhage


name: Level 9 molecular pathology procedure - Full gene sequence analysis of collagen, type IV, alpha 5 (COL4A5) for evaluation of Alport syndrome


name: Level 9 molecular pathology procedure - Full gene sequence analysis of dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive] (DYSF) for evaluation of limb-girdle muscular dystrophy


name: Level 9 molecular pathology procedure - Full gene sequence analysis of dystrophin (DMD) for evaluation of Duchenne/Becker muscular dystrophy


name: Level 9 molecular pathology procedure - Full gene sequence analysis of fibrillin 1 (FBN1) for evaluation of Marfan syndrome


name: Level 9 molecular pathology procedure - Full gene sequence analysis of inositol 1,4,5-trisphosphate receptor, type 1 (ITPR1) for evaluation of spinocerebellar ataxia


name: Level 9 molecular pathology procedure - Full gene sequence analysis of laminin, alpha 2 (LAMA2) for the evaluation of congenital muscular dystrophy


name: Level 9 molecular pathology procedure - Full gene sequence analysis of leucine-rich repeat kinase 2 (LRRK2) for evaluation of Parkinson disease


name: Level 9 molecular pathology procedure - Full gene sequence analysis of myosin, heavy chain 11, smooth muscle (MYH11) for evaluation of aortic dissections


name: Level 9 molecular pathology procedure - Full gene sequence analysis of myosin, heavy chain 11, smooth muscle (MYH11) for evaluation of thoracic aortic aneurysms


name: Level 9 molecular pathology procedure - Full gene sequence analysis of myosin, heavy chain 11, smooth muscle (MYH11) for evaluation of thoracic aortic aneurysms and aortic dissections


name: Level 9 molecular pathology procedure - Full gene sequence analysis of nebulin (NEB) for evaluation of nemaline myopathy 2


name: Level 9 molecular pathology procedure - Full gene sequence analysis of neurofibromin 1 (NF1) for evaluation of neurofibromatosis, type 1


name: Level 9 molecular pathology procedure - Full gene sequence analysis of polycystic kidney and hepatic disease 1 (PKHD1) for evaluation of autosomal recessive polycystic kidney disease


name: Level 9 molecular pathology procedure - Full gene sequence analysis of ryanodine receptor 1, skeletal (RYR1) for the evaluation of malignant hyperthermia


name: Level 9 molecular pathology procedure - Full gene sequence analysis of ryanodine receptor 2 [cardiac] (RYR2) for evaluation of arrhythmogenic right ventricular dysplasia


name: Level 9 molecular pathology procedure - Full gene sequence analysis of ryanodine receptor 2 [cardiac] (RYR2) for evaluation of catecholaminergic polymorphic ventricular tachycardia


name: Level 9 molecular pathology procedure - Full gene sequence analysis of vacuolar protein sorting 13 homolog B [yeast] (VPS13B) for evaluation of Cohen syndrome


name: Level 9 molecular pathology procedure - Full gene sequence analysis of von Willebrand factor (VWF) for evaluation of von Willebrand disease type 1


name: Level 9 molecular pathology procedure - Full gene sequence analysis of von Willebrand factor (VWF) for evaluation of von Willebrand disease type 3


name: Level 9 molecular pathology procedure - Full gene sequence analysis of von Willebrand factor (VWF) for evaluation of von Willebrand disease types 1 and 3


name: Level 9 molecular pathology procedure - Inositol 1,4,5-trisphosphate receptor, type 1 (ITPR1) full gene sequence analysis


name: Level 9 molecular pathology procedure - Laminin, alpha 2 (LAMA2) full gene sequence analysis


name: Level 9 molecular pathology procedure - Leucine-rich repeat kinase 2 (LRRK2) full gene sequence analysis


name: Level 9 molecular pathology procedure - Myosin, heavy chain 11, smooth muscle (MYH11) full gene sequence analysis


name: Level 9 molecular pathology procedure - Nebulin (NEB) full gene sequence analysis


name: Level 9 molecular pathology procedure - Polycystic kidney and hepatic disease 1 (PKHD1) full gene sequence analysis


name: Level 9 molecular pathology procedure - Ryanodine receptor 2 [cardiac] (RYR2) full gene sequence analysis


name: Level 9 molecular pathology procedure - Ryanodine receptor 2 [cardiac] (RYR2) targeted sequence analysis of >50 exons


name: Level 9 molecular pathology procedure - Targeted sequence analysis of >50 exons of ryanodine receptor 2 [cardiac] (RYR2) for evaluation of arrhythmogenic right ventricular dysplasia


name: Level 9 molecular pathology procedure - Targeted sequence analysis of >50 exons of ryanodine receptor 2 [cardiac] (RYR2) for evaluation of catecholaminergic polymorphic ventricular tachycardia


name: Level 9 molecular pathology procedure - Vacuolar protein sorting 13 homolog B [yeast] (VPS13B) full gene sequence analysis


name: Level 9 molecular pathology procedure -Collagen, type I, alpha 2 (COL1A2) full gene sequence analysis full gene sequence analysis


name: Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed


name: Genomic sequence analysis panel of DNA or combined DNA and RNA of 5-50 genes associated with solid organ abnormal growth of tissue


name: Genomic sequence analysis panel with DNA analysis of 5-50 genes associated with solid organ neoplasm


name: Genomic sequence analysis panel with DNA analysis of 5-50 genes associated with solid organ neoplasm, with interrogation for sequence variants and copy variants or rearrangements


name: Genomic sequence analysis panel with combined DNA and RNA analysis of 5-50 genes associated with solid organ neoplasm


name: Genomic sequence analysis panel with combined DNA and RNA analysis of 5-50 genes associated with solid organ neoplasm, with interrogation for sequence variants and copy number variants or rearrangements


name: Genomic sequence analysis panel of RNA of 5-50 genes associated with solid organ abnormal growth of tissue


name: Genomic sequence analysis panel with RNA analysis of 5-50 genes associated with solid organ neoplasm


name: Genomic sequence analysis panel with RNA analysis of 5-50 genes associated with solid organ neoplasm, with interrogation for sequence variants and copy number variants or rearrangements


name: Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed


name: Genomic sequence analysis panel of DNA or combined DNA and RNA of 5-50 genes associated with blood and lymphatic system disorders


name: Genomic sequence analysis panel with DNA analysis of 5-50 genes associated with hematolymphoid disease


name: Genomic sequence analysis panel with DNA analysis of 5-50 genes associated with hematolymphoid disease, with interrogation for sequence variants and copy variants or rearrangements


name: Genomic sequence analysis panel with DNA analysis of 5-50 genes associated with hematolymphoid disease, with isoform expression levels


name: Genomic sequence analysis panel with DNA analysis of 5-50 genes associated with hematolymphoid disease, with mRNA expression level


name: Genomic sequence analysis panel with combined DNA and RNA analysis of 5-50 genes associated with hematolymphoid disease


name: Genomic sequence analysis panel with combined DNA and RNA analysis of 5-50 genes associated with hematolymphoid disease, with isoform expression levels


name: Genomic sequence analysis with combined DNA and RNA analysis of 5-50 genes associated with hematolymphoid disease, with interrogation for sequence variants and copy number variants or rearrangements


name: Genomic sequence analysis with combined DNA and RNA analysis of 5-50 genes associated with hematolymphoid disease, with mRNA expression level


name: Genomic sequence analysis panel of RNA of 5-50 genes associated with blood and lymphatic system disorders


name: Genomic sequence panel with RNA analysis of 5-50 genes associated with hematolymphoid disorders, with interrogation for sequence variants and copy number variants or rearrangements


name: Genomic sequence panel with RNA analysis of 5-50 genes associated with hematolymphoid disorders, with isoform expression levels


name: Genomic sequence panel with RNA analysis of 5-50 genes associated with hematolymphoid disorders, with mRNA expression levels


name: Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed


name: Genomic sequence analysis panel of DNA or combined DNA and RNA of 51 or more genes associated with blood and lymphatic system disorders


name: Genomic sequence analysis with DNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder


name: Genomic sequence analysis with DNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with interrogation for sequence variants and copy number variants and rearrangements


name: Genomic sequence analysis with DNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with isoform expression level


name: Genomic sequence analysis with DNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with mRNA expression level


name: Genomic sequence analysis with DNA and RNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with interrogation for sequence variants and copy variants and rearrangements


name: Genomic sequence analysis with DNA and RNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with isoform expression level


name: Genomic sequence analysis with DNA and RNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with mRNA expression level


name: Genomic sequence analysis with combined DNA and RNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder


name: Genomic sequence analysis panel of RNA of 51 or more genes associated with blood and lymphatic system disorders


name: Genomic sequence analysis with RNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with interrogation for isoform expression


name: Genomic sequence analysis with RNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with interrogation for mRNA expression levels


name: Genomic sequence analysis with RNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with interrogation for sequence variants and copy number variants and rearrangement


name: Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants


name: Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, microsatellite instability


name: Genomic sequence analysis panel of DNA for microsatellite instability in solid organ abnormal growth of tissue


name: Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, copy number variants and microsatellite instability


name: Genomic sequence analysis panel of DNA for microsatellite instability and copy number of variants in solid organ abnormal growth of tissue


name: Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements


name: Genomic sequence analysis panel of DNA or combined DNA and RNA for copy number variants, microsatellite instability, tumor mutation burden, and rearrangements in solid organ abnormal growth of tissue


name: Genomic sequence analysis panel with DNA analysis associated with solid organ neoplasm, interrogation for sequence variants, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements


name: Genomic sequence analysis with combined DNA and RNA analysis associated with solid organ neoplasm, with interrogation for sequence variants, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements


name: Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants


name: Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants and rearrangements


name: Genomic sequence analysis of DNA or combined DNA and RNA in plasma for copy number variants and rearrangements in solid organ abnormal growth of tissue


name: Genomic sequence analysis panel with DNA analysis of cell-free nucleic acid associated with solid organ neoplasm, interrogation for sequence variants, copy number variants and rearrangements


name: Genomic sequence analysis panel with combined DNA and RNA analysis of cell-free nucleic acid associated with solid organ neoplasm, interrogation for sequence variants, copy number variants and rearrangements


name: Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis, copy number variants, and microsatellite instability


name: Genomic sequence analysis of DNA in plasma for copy number variants and microsatellite instability in solid organ abnormal growth of tissue


name: Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements


name: Genomic sequence analysis of DNA or combined DNA and RNA in plasma for copy number variants, microsatellite instability, tumor mutation burden, and rearrangements in solid organ abnormal growth of tissue


name: Genomic sequence analysis panel with DNA analysis of cell-free nucleic acid associated with solid organ neoplasm, interrogation for sequence variants, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements


name: Genomic sequence analysis panel with combined DNA and RNA analysis of cell-free nucleic acid associated with solid organ neoplasm, with interrogation for sequence variants, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements


name: Test for detecting 3 biomarkers associated with risk for liver disease


name: Detection of Hepatitis B surface antigen (HBsAg)


name: Quantitative detection of Hepatitis B surface antigen (HBsAg) by enzyme linked immunoassay (EIA)


name: Quantitative detection of Hepatitis B surface antigen (HBsAg) by enzyme-linked immunosorbent assay (ELISA)


name: Quantitative detection of Hepatitis B surface antigen (HBsAg) by fluorescence immunoassay (FIA)


name: Quantitative detection of Hepatitis B surface antigen (HBsAg) by immunochemiluminometric assay (IMCA)


name: Infectious agent detection by nucleic acid (DNA or RNA); hepatitis D (delta), quantification, including reverse transcription, when performed


name: Detection of hepatitis D (delta) by DNA nucleic acid quantification


name: Detection of hepatitis D (delta) by DNA nucleic acid quantification with reverse transcription


name: Detection of hepatitis D (delta) by RNA nucleic acid quantification


name: Detection of hepatitis D (delta) by RNA nucleic acid quantification with reverse transcription


name: Detection of Orthopox virus nucleic acid by amplified DNA probe technique


name: Targeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence or absence of variants and associated therapy(ies) to consider


name: DNA and RNA targeted sequencing analysis of 1-23 genes associated with non-small cell lung cancer, reported as presence/absence of variants and associated therapies to consider


name: Genomic sequence analysis of 22 genes for detection of abnormalities associated with autosomal dominant congenital thrombocytopenia (low platelet count)


name: Genomic sequence analysis of 22 genes associated with autosomal dominant congenital thrombocytopenia in amniotic fluid


name: Genomic sequence analysis of 22 genes associated with autosomal dominant congenital thrombocytopenia in blood


name: Genomic sequence analysis of 22 genes associated with autosomal dominant congenital thrombocytopenia in buccal swab


name: Genomic sequence analysis of 24 genes for detection of abnormalities associated with congenital neutropenia (low white blood cell count)


name: Genomic sequence analysis of 24 genes associated with congenital neutropenia in amniotic fluid


name: Genomic sequence analysis of 24 genes associated with congenital neutropenia in blood


name: Genomic sequence analysis of 24 genes associated with congenital neutropenia in buccal swab


name: Comprehensive genomic sequence analysis of 60 genes for detection of abnormalities associated with congenital bleeding disorders


name: Comprehensive deletion analysis of PLAU associated with genetic bleeding disorders in amniotic fluid


name: Comprehensive deletion analysis of PLAU associated with genetic bleeding disorders in blood


name: Comprehensive deletion analysis of PLAU associated with genetic bleeding disorders in buccal swab


name: Comprehensive deletion and duplication analysis of PLAU associated with genetic bleeding disorders in amniotic fluid


name: Comprehensive deletion and duplication analysis of PLAU associated with genetic bleeding disorders in blood


name: Comprehensive deletion and duplication analysis of PLAU associated with genetic bleeding disorders in buccal swab


name: Comprehensive duplication analysis of PLAU associated with genetic bleeding disorders in amniotic fluid


name: Comprehensive duplication analysis of PLAU associated with genetic bleeding disorders in blood


name: Comprehensive duplication analysis of PLAU associated with genetic bleeding disorders in buccal swab


name: Comprehensive genomic sequence analysis of 60 genes and duplication/deletion analysis of PLAU associated with genetic bleeding disorders in amniotic fluid


name: Comprehensive genomic sequence analysis of 60 genes and duplication/deletion analysis of PLAU associated with genetic bleeding disorders in blood


name: Comprehensive genomic sequence analysis of 60 genes and duplication/deletion analysis of PLAU associated with genetic bleeding disorders in buccal swab


name: Comprehensive genomic sequence analysis of 60 genes associated with genetic bleeding disorders in amniotic fluid


name: Comprehensive genomic sequence analysis of 60 genes associated with genetic bleeding disorders in blood


name: Comprehensive genomic sequence analysis of 60 genes associated with genetic bleeding disorders in buccal swab


name: Genomic sequence analysis of 62 genes for detection of abnormalities associated with genetic platelet disorders


name: Deletion and duplication analysis of PLAU associated with genetic platelet disorders in amniotic fluid


name: Deletion and duplication analysis of PLAU associated with genetic platelet disorders in blood


name: Deletion and duplication analysis of PLAU associated with genetic platelet disorders in blood, buccal swab, or amniotic fluid


name: Deletion and duplication analysis of PLAU associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 62 genes and deletion analysis of PLAU associated with genetic platelet disorders in amniotic fluid


name: Genomic sequence analysis of 62 genes and deletion analysis of PLAU associated with genetic platelet disorders in blood


name: Genomic sequence analysis of 62 genes and deletion analysis of PLAU associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 62 genes and duplication analysis of PLAU associated with genetic platelet disorders in amniotic fluid


name: Genomic sequence analysis of 62 genes and duplication analysis of PLAU associated with genetic platelet disorders in blood


name: Genomic sequence analysis of 62 genes and duplication analysis of PLAU associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 62 genes and duplication and deletion analysis of PLAU associated with genetic platelet disorders in amniotic fluid


name: Genomic sequence analysis of 62 genes and duplication and deletion analysis of PLAU associated with genetic platelet disorders in blood


name: Genomic sequence analysis of 62 genes and duplication and deletion analysis of PLAU associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 62 genes associated with genetic platelet disorders in amniotic fluid


name: Genomic sequence analysis of 62 genes associated with genetic platelet disorders in blood


name: Genomic sequence analysis of 62 genes associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 40 genes for detection of abnormalities associated with genetic platelet function disorder


name: Deletion analysis of PLAU associated with genetic platelet function disorder in amniotic fluid


name: Deletion analysis of PLAU associated with genetic platelet function disorder in blood


name: Deletion analysis of PLAU associated with genetic platelet function disorder in blood, buccal swab, or amniotic fluid


name: Deletion analysis of PLAU associated with genetic platelet function disorder in buccal swab


name: Deletion and duplication analysis of PLAU associated with genetic platelet function disorder in amniotic fluid


name: Deletion and duplication analysis of PLAU associated with genetic platelet function disorder in blood


name: Deletion and duplication analysis of PLAU associated with genetic platelet function disorder in blood, buccal swab, or amniotic fluid


name: Deletion and duplication analysis of PLAU associated with genetic platelet function disorder in buccal swab


name: Duplication analysis of PLAU associated with genetic platelet function disorder in amniotic fluid


name: Duplication analysis of PLAU associated with genetic platelet function disorder in blood


name: Duplication analysis of PLAU associated with genetic platelet function disorder in blood, buccal swab, or amniotic fluid


name: Duplication analysis of PLAU associated with genetic platelet function disorder in buccal swab


name: Genomic sequence analysis of 40 genes and analysis of PLAU associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 40 genes and deletion analysis of PLAU associated with genetic platelet disorders in amniotic fluid


name: Genomic sequence analysis of 40 genes and deletion analysis of PLAU associated with genetic platelet disorders in blood


name: Genomic sequence analysis of 40 genes and deletion analysis of PLAU associated with genetic platelet disorders in blood, buccal swab, or amniotic fluid


name: Genomic sequence analysis of 40 genes and deletion analysis of PLAU associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 40 genes and deletion and duplication analysis of PLAU associated with genetic platelet disorders in amniotic fluid


name: Genomic sequence analysis of 40 genes and deletion and duplication analysis of PLAU associated with genetic platelet disorders in blood


name: Genomic sequence analysis of 40 genes and deletion and duplication analysis of PLAU associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 40 genes and duplication analysis of PLAU associated with genetic platelet disorders in amniotic fluid


name: Genomic sequence analysis of 40 genes and duplication analysis of PLAU associated with genetic platelet disorders in blood


name: Genomic sequence analysis of 40 genes and duplication analysis of PLAU associated with genetic platelet disorders in blood, buccal swab, or amniotic fluid


name: Genomic sequence analysis of 40 genes associated with genetic platelet function disorder in amniotic fluid


name: Genomic sequence analysis of 40 genes associated with genetic platelet function disorder in blood


name: Genomic sequence analysis of 14 genes for detection of abnormalities associated with genetic thrombosis (excessive clotting)


name: Genomic sequence analysis of 12 genes associated with genetic thrombosis in buccal swab


name: Genomic sequence analysis of 14 genes associated with genetic thrombosis in amniotic fluid


name: Genomic sequence analysis of 14 genes associated with genetic thrombosis in blood


name: Analysis of 3 proteins in plasma specimen, algorithm reported as risk score for obstructive coronary heart disease


name: Evaluation of 17 DNA biomarkers reported as a risk score for cancer recurrence


name: Enzyme immunoassay analysis of beta-amyloid fragments in cerebral spinal fluid to evaluate mild mental impairment


name: Phase separation and immunoassay evaluation of prostate-specific antigen (PSA) in plasma to evaluate risk of prostate cancer


name: Enzyme-linked immunosorbent assay of autoantibodies in plasma to evaluate risk of malignancy in lung cancer


name: Gene-expression profiling--enrichment RNA sequencing of 82 content genes and 10 housekeeping genes reported as one of three molecular subtypes in papillary thyroid cancer


name: Gene-expression profiling via targeted hybrid capture-enrichment RNA sequencing of 82 content genes and 10 housekeeping genes in fine needle aspirate tissue, algorithm reported as one of three molecular subtypes for evaluation of papillary thyroid cancer


name: Gene-expression profiling via targeted hybrid capture-enrichment RNA sequencing of 82 content genes and 10 housekeeping genes in formalin-fixed paraffin embedded (FFPE) tissue, algorithm reported as one of three molecular subtypes for evaluation of papillary thyroid cancer


name: Gene-expression profiling of 5 genes in urine reported as a risk score for having urothelial carcinoma


name: Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of minimal residual disease (MRD) with quantitation of disease burden, when appropriate


name: Genomic sequence testing for presence or absence of cancer cells after treatment in leukemia or lymphoma


name: Genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of minimal residual disease (MRD) in hematolymphoid neoplasm


name: Oncology (bladder), 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, diagnostic algorithm, including patient's age, race, and gender, reported as a probability of harboring urothelial cancer


name: Test for 10 protein biomarkers for bladder cancer


name: Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, algorithm reported as a probability of recurrent bladder cancer


name: Test for 10 protein biomarkers for recurrent bladder cancer


name: Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection


name: Test for 10 protein biomarkers for rapid recurrent, recurrent, or persistent bladder cancer after bladder surgery to remove a tumor


name: Immunoassay analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) in urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of persistent cancer following transurethral resection


name: Immunoassay analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) in urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent cancer following transurethral resection


name: Immunoassay analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) in urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection


name: Oncology (colorectal cancer), evaluation for mutations of APC, BRAF, CTNNB1, KRAS, NRAS, PIK3CA, SMAD4, and TP53, and methylation markers (MYO1G, KCNQ5, C9ORF50, FLI1, CLIP4, ZNF132, and TWIST1), multiplex quantitative polymerase chain reaction (qPCR), circulating cell-free DNA (cfDNA), plasma, report of risk score for advanced adenoma or colorectal cancer


name: Multiplex quantitative polymerase chain reaction (qPCR) evaluation for mutations of APC, BRAF, CTNNB1, KRAS, NRAS, PIK3CA, SMAD4, and TP53, and methylation markers (MYO1G, KCNQ5, C9ORF50, FLI1, CLIP4, ZNF132 and TWIST1) in plasma circulating cell-free DNA (cfDNA), reported as a risk score for advanced adenoma


name: Multiplex quantitative polymerase chain reaction (qPCR) evaluation for mutations of APC, BRAF, CTNNB1, KRAS, NRAS, PIK3CA, SMAD4, and TP53, and methylation markers (MYO1G, KCNQ5, C9ORF50, FLI1, CLIP4, ZNF132 and TWIST1) in plasma circulating cell-free DNA (cfDNA), reported as a risk score for colorectal cancer


name: Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative polymerase chain reaction (qPCR), urine


name: Test for 16 genitourinary bacterial organisms and 1 genitourinary fungal organism


name: Identification of DNA from 16 bacterial organisms and 1 fungal organism in urine by multiplex DNA amplified probe technique via quantitative polymerase chain reaction (qPCR)


name: Identification of DNA from 16 bacterial organisms and 1 fungal organism in urine by multiplex DNA or RNA amplified probe technique via quantitative polymerase chain reaction (qPCR)


name: Identification of DNA from 16 bacterial organisms and 1 fungal organism in urine by multiplex RNA amplified probe technique via quantitative polymerase chain reaction (qPCR)


name: Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, reported as an antimicrobial stewardship risk score


name: Test for genitourinary pathogen antibiotic-resistance genes


name: Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score


name: Test for proteins to determine risk for ovarian cancer


name: Oncology (prostate cancer), image analysis of at least 128 histologic features and clinical factors, prognostic algorithm determining the risk of distant metastases, and prostate cancer-specific mortality, includes predictive algorithm to androgen deprivation-therapy response, if appropriate


name: Test to determine potential risk of prostate cancer spread and mortality


name: Image analysis of at least 128 histologic features and clinical factors, prognostic algorithm determining the risk of distant metastases, and prostate cancer-specific mortality


name: Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables)


name: Test of lipoprotein profile in cardiovascular disease


name: RFC1 (replication factor C subunit 1), repeat expansion variant analysis by traditional and repeat-primed PCR, blood, saliva, or buccal swab


name: Test for RFC1 (replication factor C subunit 1) in neurological conditions


name: Repeat expansion variant analysis of replication factor C subunit 1 (RFC1 by traditional and repeat-primed PCR in blood


name: Repeat expansion variant analysis of replication factor C subunit 1 (RFC1 by traditional and repeat-primed PCR in buccal swab


name: Repeat expansion variant analysis of replication factor C subunit 1 (RFC1 by traditional and repeat-primed PCR in saliva


name: Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA (55 genes) by next-generation sequencing, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutational burden


name: Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis, 20 gene variants and CYP2D6 deletion or duplication analysis with reported genotype and phenotype


name: Test for adverse drug reactions and drug response


name: Maple syrup urine disease monitoring by patient-collected blood card sample, quantitative measurement of allo-isoleucine, leucine, isoleucine, and valine, liquid chromatography with tandem mass spectrometry (LC-MS/MS)


name: Test for monitoring maple syrup urine disease


name: Hyperphenylalaninemia monitoring by patient-collected blood card sample, quantitative measurement of phenylalanine and tyrosine, liquid chromatography with tandem mass spectrometry (LC-MS/MS)


name: Test for monitoring hyperphenylalaninemia


name: Tyrosinemia type I monitoring by patient-collected blood card sample, quantitative measurement of tyrosine, phenylalanine, methionine, succinylacetone, nitisinone, liquid chromatography with tandem mass spectrometry (LC-MS/MS)


name: Nephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and HbA1c and estimated glomerular filtration rate (GFR), with risk score reported for predictive progression to high-stage kidney disease


name: Test for predictive risk of progression of high-stage kidney disease


name: Nephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, algorithm combining results with HDL, estimated glomerular filtration rate (GFR) and clinical data reported as a risk score for developing diabetic kidney disease


name: Testing for risk of developing diabetic kidney disease


name: Oncology (melanoma), autophagy and beclin 1 regulator 1 (AMBRA1) and loricrin (AMLo) by immunohistochemistry, formalin-fixed paraffin-embedded (FFPE) tissue, report for risk of progression


name: Tissue evaluation for proteins to report risk of skin cancer progression


name: Oncology (non-small cell lung cancer), next-generation sequencing with identification of single nucleotide variants, copy number variants, insertions and deletions, and structural variants in 37 cancer-related genes, plasma, with report for alteration detection


name: Next-generation sequencing in plasma of 37 cancer-related genes, with report for alteration detection in non-small cell lung cancer


name: Pediatric febrile illness (Kawasaki disease [KD]), interferon alpha-inducible protein 27 (IFI27) and mast cell-expressed membrane protein 1 (MCEMP1), RNA, using quantitative reverse transcription polymerase chain reaction (RT-qPCR), blood, reported as a risk score for KD


name: Reverse transcription polymerase chain reaction (RT-qPCR) testing of blood for proteins, reported as a risk score for Kawasaki disease


name: Obstetrics (preeclampsia), kinase insert domain receptor (KDR), Endoglin (ENG), and retinol-binding protein 4 (RBP4), by immunoassay, serum, algorithm reported as a risk score


name: Immunoassay of serum for proteins, reported as a risk score for preeclampsia


name: Oncology (solid tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded (FFPE) tissue, 437 genes, interpretive report for single nucleotide variants, splice-site variants, insertions/deletions, copy number alterations, gene fusions, tumor mutational burden, and microsatellite instability, with algorithm quantifying immunotherapy response score


name: DNA and RNA next-generation sequencing of tissue for 437 genes with algorithm quantifying immunotherapy response score


name: Drug metabolism (depression, anxiety, attention deficit hyperactivity disorder [ADHD]), gene-drug interactions, variant analysis of 16 genes, including deletion/duplication analysis of CYP2D6, reported as impact of gene-drug interaction for each drug


name: Evaluation of gene-drug interactions for 16 genes reported as impact of gene-drug interaction for each drug for depression, anxiety, attention deficit disorder


name: Variant analysis of 16 genes including deletion analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in anxiety


name: Variant analysis of 16 genes including deletion analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in attention deficit hyperactivity disorder [ADHD]


name: Variant analysis of 16 genes including deletion analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in depression


name: Variant analysis of 16 genes including deletion analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in depression, anxiety, attention deficit hyperactivity disorder [ADHD]


name: Variant analysis of 16 genes including deletion and duplication analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in anxiety


name: Variant analysis of 16 genes including deletion and duplication analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in attention deficit hyperactivity disorder [ADHD]


name: Variant analysis of 16 genes including deletion and duplication analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in depression


name: Variant analysis of 16 genes including duplication analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in anxiety


name: Variant analysis of 16 genes including duplication analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in attention deficit hyperactivity disorder [ADHD]


name: Variant analysis of 16 genes including duplication analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in depression


name: Variant analysis of 16 genes including duplication analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in depression, anxiety, attention deficit hyperactivity disorder [ADHD]


name: Neurology (eg, Parkinson disease, dementia with Lewy bodies), cerebrospinal fluid (CSF), detection of misfolded α-synuclein protein by seed amplification assay, qualitative


name: Detection of protein by seed amplification assay for neurological disorders


name: Detection of misfolded α-synuclein protein by qualitative seed amplification assay in cerebrospinal fluid (CSF) in Parkinson disease


name: Detection of misfolded α-synuclein protein by qualitative seed amplification assay in cerebrospinal fluid (CSF) in dementia with Lewy bodies


name: Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 16 PFAS compounds by liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative


name: Testing of plasma or serum for 16 perfluoroalkyl substances (PFAS) compounds


name: Evaluation of 16 perfluoroalkyl substances (PFAS) compounds by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in plasma


name: Evaluation of 16 perfluoroalkyl substances (PFAS) compounds by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in plasma or serum


name: Evaluation of 16 perfluoroalkyl substances (PFAS) compounds by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in serum


name: Evaluation of perfluorooctane sulfonic acid by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in plasma


name: Evaluation of perfluorooctane sulfonic acid by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in plasma or serum


name: Evaluation of perfluorooctane sulfonic acid by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in serum


name: Evaluation of perfluorooctanoic acid by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in plasma


name: Evaluation of perfluorooctanoic acid by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in plasma or serum


name: Evaluation of perfluorooctanoic acid by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in serum


name: Oncology (lung), multi-omics (microbial DNA by shotgun next-generation sequencing and carcinoembryonic antigen and osteopontin by immunoassay), plasma, algorithm reported as malignancy risk for lung nodules in early-stage disease


name: Multi-omics testing of plasma reported as risk of malignancy for lung nodules in early-stage lung cancer


name: Gastroenterology (Barrett's esophagus), P16, RUNX3, HPP1, and FBN1 DNA methylation analysis using PCR, formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as risk score for progression to high-grade dysplasia or cancer


name: DNA methylation analysis using polymerase chain reaction testing of tissue for genes specific to Barrett esophagus, reported as a risk score for progression to high grade dysplasia or cancer


name: Neurology (cerebral folate deficiency), serum, detection of anti-human folate receptor IgG-binding antibody and blocking autoantibodies by enzyme-linked immunoassay (ELISA), qualitative, and blocking autoantibodies, using a functional blocking assay for IgG or IgM, quantitative, reported as positive or not detected


name: Enzyme-linked assay detection in serum of IgG-binding antibody and blocking autoantibodies, using a functional blocking assay for IgG or IgM reported as positive or not detected in cerebral folate deficiency


name: Enzyme-linked immunoassay (ELISA) for detection of anti-human folate receptor IgG-binding antibody and blocking autoantibodies in serum using a functional blocking assay for IgG or IgM, quantitative, reported as positive or not detected in cerebral folate deficiency


name: Obstetrics (expanded carrier screening), 145 genes by next-generation sequencing, fragment analysis and multiplex ligation-dependent probe amplification, DNA, reported as carrier positive or negative


name: Next-generation sequencing of DNA for 145 genes reported as carrier positive or negative in expanded carrier screening


name: Cardiology (coronary heart disease [CHD]), 9 genes (12 variants), targeted variant genotyping, blood, saliva, or buccal swab, algorithm reported as a genetic risk score for a coronary event


name: Targeted variant genotyping using blood, saliva, or buccal swab of 9 genes for coronary heart disease reported as a risk score for a coronary event


name: Targeted variant genotyping of 9 genes (12 variants) in blood, algorithm reported as a genetic risk score for a coronary event in coronary heart disease [CAD]


name: Targeted variant genotyping of 9 genes (12 variants) in buccal swab, algorithm reported as a genetic risk score for a coronary event in coronary heart disease [CAD]


name: Targeted variant genotyping of 9 genes (12 variants) in saliva, algorithm reported as a genetic risk score for a coronary event in coronary heart disease [CAD]


name: Infectious agent (sexually transmitted infection), Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, multiplex amplified probe technique, vaginal, endocervical, or male urine, each pathogen reported as detected or not detected


name: Detection of organisms causing sexually transmitted infection by multiplex amplified probe technique


name: Detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium in endocervical specimen using multiplex amplified probe technique, each pathogen reported as detected or not detected


name: Detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium in male urine specimen using multiplex amplified probe technique, each pathogen reported as detected or not detected


name: Detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium in vaginal specimen using multiplex amplified probe technique, each pathogen reported as detected or not detected


name: Oncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch urine, algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer


name: mRNA expression profiling of 18 genes to detect potential risk of prostate cancer


name: Oncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, results reported as risk of disease progression


name: Analysis of serum using immunoassay technique for thymidine kinase activity in breast cancer


name: Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected


name: Sequencing of methylation haplotype block markers in plasma in pancreatic cancer


name: Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4-carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer


name: Flow cytometry detection of 5 markers in sputum to evaluate potential for lung cancer


name: Nephrology (diabetic chronic kidney disease [CKD]), multiplex electrochemiluminescent immunoassay (ECLIA) of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function


name: Measurement of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) to evaluate risk of progressive decline in kidney function in diabetic chronic kidney disease


name: Infectious agent antigen detection by bulk acoustic wave biosensor immunoassay, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])


name: Oncology (solid tumor), DNA (80 genes) and RNA (36 genes), by next-generation sequencing from plasma, including single nucleotide variants, insertions/deletions, copy number alterations, microsatellite instability, and fusions, report showing identified mutations with clinical actionability


name: Next-generation sequencing of DNA (80 genes) and RNA (39 genes) in plasma showing mutations and clinical actionability in solid tumor cancers


name: Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected


name: Whole genome sequencing of DNA in whole blood or plasma to detect pancreatic cancer


name: Whole genome DNA sequencing with hydroxymethylcytosine enrichment in plasma, algorithm reported as cancer detected or not detected in pancreatic cancer


name: Whole genome DNA sequencing with hydroxymethylcytosine enrichment in whole blood or plasma, algorithm reported as cancer detected or not detected in pancreatic cancer


name: Whole genome DNA sequencing with hydroxymethylcytosine enrichment in whole blood, algorithm reported as cancer detected or not detected in pancreatic cancer


name: Genomic analysis of 15 genes to evaluate for psychiatric disorders


name: Genomic analysis panel with variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 in anxiety


name: Genomic analysis panel with variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 in attention deficit hyperactivity disorder (ADHD)


name: Genomic analysis panel with variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 in depression


name: Genomic analysis panel with variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 in depression, anxiety, attention deficit hyperactivity disorder (ADHD)


name: Beta amyloid, Aβ42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology


name: Measurement of Aβ42/40 ratio in plasma to evaluation for brain amyloid pathology


name: Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow, report of clinically significant alterations


name: Optical genome mapping of DNA in blood or bone marrow for changes in copy number alterations, aneuploidy, and balanced/complex structural rearrangements in blood and lymphatic system abnormal tissue


name: Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1, if performed, formalin-fixed paraffin-embedded (FFPE) tissue, reported as positive or negative for each biomarker


name: Whole slide imaging analysis for 8 genes for evaluation of lung cancer


name: Evaluation for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1) and nd KRAS G12C and PD-L1 if performed, in formalin-fixed paraffin-embedded (FFPE) tissue by whole slide imaging analysis, reported as positive or negative for each biomarker in lung cancer


name: Cardiovascular disease (acute coronary syndrome [ACS]), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year (deleted risk) score for ACS


name: Test of biomarkers in blood combined with patient factors to determine a 5-year risk score for acute coronary syndrome


name: Detection of DNA of 20 organisms in urine


name: Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclear-encoded mitochondrial gene analysis of 335 nuclear genes, including sequence changes, deletions, insertions, and copy number variants analysis, blood or saliva, identification and categorization of mitochondrial disorder-associated genetic variants


name: Whole genome sequence analysis of 335 nuclear genes in blood or saliva for detection of abnormalities associated with rare constitutional/heritable diseases


name: Evaluation of 355 nuclear genes in blood by whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, including sequence changes, deletions, insertions, and copy number variants analysis, identification and categorization of mitochondrial disorder-associated genetic variants


name: Evaluation of 355 nuclear genes in blood or saliva by whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, including sequence changes, deletions, insertions, and copy number variants analysis, identification and categorization of mitochondrial disorder-associated genetic variants


name: Evaluation of 355 nuclear genes in saliva by whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, including sequence changes, deletions, insertions, and copy number variants analysis, identification and categorization of mitochondrial disorder-associated genetic variants


name: Oncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, reported as a recurrence score


name: Image analysis of breast cancer cell specimen with autonomous assessment


name: Evaluation of 8 histologic and immunohistochemical features by image analysis and autonomous assessment, reported as a recurrence score for breast cancer


name: Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype


name: Genomic sequence analysis of 13 genes in saliva for evolution of psychiatric disorders


name: Genomic sequence analysis panel of 13 genes in buccal swab, with report of each gene phenotype in anxiety


name: Genomic sequence analysis panel of 13 genes in buccal swab, with report of each gene phenotype in depression


name: Genomic sequence analysis panel of 13 genes in buccal swab, with report of each gene phenotype in depression, anxiety


name: Genomic sequence analysis panel of 13 genes in saliva or buccal swab, with report of each gene phenotype in anxiety


name: Genomic sequence analysis panel of 13 genes in saliva or buccal swab, with report of each gene phenotype in depression


name: Genomic sequence analysis panel of 13 genes in saliva or buccal swab, with report of each gene phenotype in depression, anxiety


name: Genomic sequence analysis panel of 13 genes in saliva, with report of each gene phenotype in anxiety


name: Genomic sequence analysis panel of 13 genes in saliva, with report of each gene phenotype in depression


name: Genomic sequence analysis panel of 13 genes in saliva, with report of each gene phenotype in depression, anxiety


name: Respiratory syncytial virus, monoclonal antibody, seasonal dose


name: Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use


name: Respiratory syncytial virus antibody, 0.5 mL dosage for injection into muscle


name: Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use


name: Respiratory syncytial virus antibody, 1.0 mL dosage for injection into muscle


name: Immunization administration by intramuscular injection, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine; first or only component of each vaccine administered


name: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use


name: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use


name: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use


name: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use


name: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use


name: Chikungunya virus vaccine, live attenuated, for intramuscular use


name: Administration of Chikungunya virus vaccine


name: Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use


name: Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use


name: Respiratory syncytial virus vaccine mRNA lipid nanoparticles


name: Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use


name: Meningococcal conjugate vaccine serogroups A, C, W, Y, B-FHbp, pentavalent, tetanus toxoid carrier


name: Diagnostic analysis, programming, and verification of an auditory osseointegrated sound processor, any type


name: Diagnostic analysis, programming, and verification of an auditory osseointegrated sound processor, any type; first 60 minutes


name: Analysis, programming, and verification of sound processor for bone-anchored inner ear implant, first hour


name: Diagnostic analysis, programming, and verification of an auditory osseointegrated sound processor, any type; each additional 15 minutes (List separately in addition to code for primary procedure)


name: Analysis, programming, and verification of sound processor for bone-anchored inner ear implant, each additional 15 minutes


name: Therapy activation of implanted phrenic nerve stimulator system, including all interrogation and programming


name: Activation of implanted phrenic nerve stimulator


name: Interrogation and programming (minimum one parameter) of implanted phrenic nerve stimulator system


name: Interrogation and programming of implanted phrenic nerve stimulator system during polysomnography


name: Evaluation and programming of implanted phrenic nerve stimulator system during sleep study


name: Interrogation without programming of implanted phrenic nerve stimulator system


name: Interrogation of implanted phrenic nerve stimulator system


name: venography for congenital heart defect, including catheter placement, radiological supervision, interpretation


name: Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; anomalous or persistent superior vena cava when it exists as a second contralateral superior vena cava, with native drainage to heart (List separately in addition to code for primary procedure)


name: Review by radiologist of vein imaging for congenital heart defect of superior vena cava


name: Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; azygos/hemiazygos venous system (List separately in addition to code for primary procedure)


name: Review by radiologist of vein imaging for congenital heart defect of the azygos/hemiazygos venous system


name: Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; coronary sinus (List separately in addition to code for primary procedure)


name: Review by radiologist of vein imaging for congenital heart defect of coronary sinus


name: Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; venovenous collaterals originating at or above the heart (eg, from innominate vein) (List separately in addition to code for primary procedure)


name: Review by radiologist of vein imaging for congenital heart defect of venovenous collaterals above the heart


name: Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation for innominate vein


name: Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; venovenous collaterals originating below the heart (eg, from the inferior vena cava) (List separately in addition to code for primary procedure)


name: Review by radiologist of vein imaging for congenital heart defect of venovenous collaterals below the heart